Lonza shuts down Swiss manufacturing site cutting 190 jobs

BIOT

featured image of Lonza shuts down Swiss manufacturing site cutting 190 jobs
📢 Lonza is decommissioning its mammalian manufacturing site in Visp, Switzerland, as part of a strategic review of its assets.

🏭 The site has been in operation for 30 years and has played a key role in the production of antibodies and other biologic drugs.

✅ The decision to decommission the site is driven by long-term market dynamics and the need for more flexible manufacturing processes.

❌ Lonza will focus on its other manufacturing sites and expand its offerings in areas such as gene and cell therapies.

😔 The decommissioning process will result in the loss of around 190 jobs at the site.

📢 Lonza shuts down Swiss manufacturing site 190 jobs lost

Introduction:

Lonza, a global leader in life sciences, has announced the decommissioning of their California mammalian manufacturing site in the United States. The decision to shut down the facility is part of Lonza’s ongoing efforts to optimize their global manufacturing network and enhance operational efficiency.

Main points:

  1. The decommissioning of the California mammalian manufacturing site is a strategic move by Lonza to improve their global manufacturing network and streamline operations.
  2. The site closure is expected to be completed by the end of 2021 and will result in the transfer of manufacturing processes and assets to other Lonza facilities.
  3. This decision is aligned with Lonza’s commitment to consolidating their operations and focusing on high-potential areas of growth in the life sciences industry.
  4. The closure of the California site will not impact Lonza’s ability to meet customers’ demand for CDMO (Contract Development and Manufacturing Organization) and other services, as the company has other manufacturing sites globally.
  5. This move will allow Lonza to allocate resources more effectively and invest in areas of the business that have higher potential for growth and profitability.

Conclusion:

Lonza’s decision to decommission the California mammalian manufacturing site is in line with the company’s strategy to optimize their global manufacturing network and improve operational efficiency. While the closure of the site may result in job losses, Lonza is committed to supporting affected employees during the transition period. Overall, this move allows Lonza to focus on areas of the business with higher growth potential and continue providing high-quality services to their customers.

Leave a Comment